Transplant Reports : Open Access

Mini Review Open Access

Report on a Case of Diabetes and Diabetic Nephropathy Co-Existing After Kidney Transplantation

Surasak Kantar*

Department of Medicine, Division of Nephrology, Ramathibodi Hospital, Thailand

Abstract

Membranous nephropathy (MN) is a glomerular complaint generally set up in scattered feathers. The natural history of MN post-transplant is changeable and robotic forgiveness is uncommon. Diabetic nephropathy (DN) is also generally seen in cases with dragged new onset diabetes mellitus after transplant (NODAT). Still, there have been no former reports of co- being MN and DN in transplanted feathers. We herein report a case of 53- time-old virile with early post-transplant proteinuria and bitsy hematuria due to MN with posterior clinical robotic forgiveness. Due to the early onset of complaint after transplant and presence of serumanti- phospholipase A2 receptor (anti-PLA2R) antibody, the validation suggests primary intermittent MN in this case. He was also diagnosed with NODAT, with fair glycaemic control with oral hypoglycaemic agents. Sixteen times after forgiveness, he developed intermittent proteinuria and progressive impairment of renal function. The allograft dissection revealed both MN and DN. Both conditions may have contributed to the development of glomerular pathology in this case.

Keywords: Diabetic nephropathy; Natural coumarins; Oxidative stress; Inflammation; Advanced glycation end products

Introduction

Membranous nephropathy(MN) is a common cause of nephrotic pattern in grown- ups and is one of the most frequent glomerular conditions set up in thepost- transplant period leading to poor allograft survival(2). New onset diabetes mellitus after transplant (NODAT) has been reported to do in 4 – 25 of renal transplant benefactors and may lead to diabetic nephropathy (DN), which results in lower allograft and case survival. Still, there has been no former reports of co- being of MN and DN in transplanted feathers. Also, we report a case of co- being post-transplant MN with DN as a complication of NODAT [1].

Material and Methods

A 53- time-old Thai joker with end- stage renal complaint (ESRD) due to hypertensive nephropathy entered an HLA-identical allograft renal transplant from his family in February 1997. He would no former history of diabetes mellitus (DM) but his ma was a diabetic. Induction treatment with methylprednisolone 1000 mg, 500 mg, and 250 mg was given on days 0, 1 and 2, singly. The conservation immunosuppressive authority comported of cyclosporine A 350 mg/ day and prednisolone 20 mg/ day. His postoperative period was uneventful and allograft function was excellent [2].

Within four months after the transplant, his serum creatinine position rose from1.2 mg/ dL to3.3 mg/ dL. Allograft dissection was performed and showed no signs of graft rejection. Cyclosporin- induced nephrotoxicity was diagnosed since the topmost cyclosporin trough position reported was 414 ng/ ml. After the capsule of cyclosporin was lowered, the serum creatinine position dropped to1.6 mg/ dL.

In 1998, he developed DM, which was controlled with glipizide 5 mg/ day and sitagliptin 100 mg/ day performing in fair glycaemic control with HbA1c situations between6.3 and8.1 (Fig. 1C). His systolic blood pressure varied between 130 and 160 mmHg and diastolic blood pressure varied between 80 and 110 mmHg(3).

In 1999, urinalysis during follow up revealed proteinuria with a urine protein of2.8 g/ day, RBC 5 – 10/ HPF with no cellular casts. Allograft dissection revealed thickening of the glomerular capillary walls in all glomeruli. An opinion of MN and hyaline arteriosclerosis was made. Enalapril was given to control proteinuria with poor response. He would robotic clinical forgiveness after 4 times of treatment [3, 4].

In 2014, he presented with bending edema in both legs, and positive dipstick proteinuria. The UPCR was1.85 g/ g, serum albumin of3.29 g/ dL, cholesterol of 185 mg/ dL andanti- phospholipase A2 receptor (anti-PLA2R) was detected in the serum. Renal ultrasonography revealed a normal appearance of the renal allograft. HBsAg, anti-HBs, Anti-HCV andante- HIV were negative. Allograft dissection was performed and showed thickened capillary wall and expanded meningeal matrix in the glomeruli weak direct IgG deposit on immunofluorescence and thickened basement membrane (510 – 614 nm.) on electron microscopy, compatible with diabetic nephropathy, class 2. In addition, coarse deposits of IgG along the capillary wall corresponded with spikes on light microscopy and foci of electron lucent and thick deposits in sub epithelium and intramembranous all features of membranous nephropathy. C4d was negative in the per tubular capillaries but positive in glomerular capillaries [5].

Discussion

We present this case Ofcom- being MN and DN in a transplant case. One time after transplantation he developed NODAT, the most common complication in renal transplant cases and has been reported to do in 4 – 25 of benefactors. The cause of NODAT in this case was allowed to be due to the side goods of the immunosuppressive agents including cyclosporine A and prednisolone combined with a family history of DM. In former studies, the domestic history of DM along with race, age, heritable background, former glucose sectarianism, obesity, hepatitis C contagion, and cytomegalovirus infection were

***Corresponding author:** Surasak Kantar, Department of Medicine, Division of Nephrology, Ramathibodi Hospital, Thailand, E-mail: SKantar_ks@r.com

Received: 01-April-2023, Manuscript No: troa-23-97061, **Editor assigned:** 03-April-2023, PreQC No: troa-23-97061 (PQ), **Reviewed:** 17-April-2023, QC No: troa-23-97061, **Revised:** 22-April-2023, Manuscript No: troa-23-97061, **Published:** 28-April-2023, DOI: 10.4172/troa.1000170

Citation: Kantar S (2023) Report on a Case of Diabetes and Diabetic Nephropathy Co-Existing After Kidney Transplantation. Transplant Rep 8: 170.

trouble factors of NODAT. The case's NODAT was fairly controlled with oral hypoglycaemic agents [6].

Two times after transplantation, he developed proteinuria and bitsy haematuria. Allograft dissection revealed thickening of the glomerular capillary walls in all glomeruli, harmonious with the histopathological features of MN. From former reports, intermittent MN passed earlier than de novo MN (15.58 ±19.13vs.49.27 ±32.71 months), our case was therefore considered as intermittent MN, which has been reported to do in2.5 of transplanted cases. Such a significant difference suggests that different mechanisms are involved in the physiopathology of these conditions. For de novo MN, HCV and patron-specific antibody feel to be the important etiologic factors. Since no given etiologist of MN including viral infection, malignancy, autoimmune complaint or cryoglobulinemia have been linked to date, we believe he has idiopathic MN. In addition, the allograft dissection also revealed hyaline arteriosclerosis, which can be set up in hypertensive nephropathy, calcineurin asset nephrotoxicity, or DN. Enalapril was given to control proteinuria but without response. He would robotic clinical forgiveness after 4 times of treatment. Robotic forgiveness of idiopathic MN has been observed among transplant cases and is a well- known point [7].

Seventeen times after transplant, he presented with leg edema and intermittent proteinuria. The demarcation judgments were intermittent MN, DN, and transplant glomerulopathy. Allograft dissection revealed histopathological features of both MN and DN. The hepatitis and HIV viral studies were negative except foranti- phospholipase A2 receptor (PLA2R) antibody which was detected in the serum. Anti-PLA2R antibody is a biomarker that can be used to separate between idiopathic and secondary MN. Therefore, it was more likely that the case had idiopathic intermittent MN. In this case, DN was linked 16 times after the opinion of NODAT. In former studies, NODAT has been reported to beget DN roughly times after transplantation [8].

Indeed though MN and DN are common in thepost- transplant periodic- actuality of MN and DN has yet to be reported. Post-transplant robotic forgiveness of MN can be observed, but MN may lead to poor allograft survival. Long standing DM after order- transplant causes significant pathological injury to the allograft, performing in lowered allograft and case survival. The United States Renal Data System (USRDS) has fluently stated the relationship between NODAT and a 63 increase in graft failure and an 85 increase in mortality. Inclusively, MN and DN have a negative impact on allograft survival. We believe that having both MN and DN may contribute to an indeed worse outgrowth than having either complaint alone.

In native feathers, all cases with MN should admit swish supportive care, including treatment with ACEI/ ARB, lipid lowering agents, and respectable control of blood pressure. The use of immunosuppressive remedy should be considered on an individual base. In this case, supportive care and immunosuppressive remedy were formerly given. It's well known that immunosuppresses are demanded to avoid graft rejection, but their salutary goods onpost- transplant MN have not yet been validated [9, 10].

Acknowledgment

None

Conflict of Interest

None

References

1. Delgado JF, Reyne AG, de Dios S, López-Medrano F, Jurado A, et al. (2015) Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation. J Heart Lung Transplant 3:1112-1119.
2. Raffa GM, Di Gesaro G, Sciacca S, Tuzzolino F, Turrisi M, et al. (2016) Heart transplant program at IRCCS-ISMETT: Impact of mechanical circulatory support on pre- and post -transplant survival. Int J Cardiol 219: 358-361.
3. Zielińska K, Kukulski L, Wróbel M, Przybyłowski P, Rokicka D, et al. (2022) Carbohydrate Metabolism Disorders in Relation to Cardiac Allograft Vasculopathy (CAV) Intensification in Heart Transplant Patients According to the Grading Scheme Developed by the International Society for Heart and Lung Transplantation (ISHLT). Ann Transplant 27: 933420.
4. Conway J, Manlhiot C, Kirk R, Edwards LB, McCrindle BW, et al. Mortality and morbidity after retransplantation after primary heart transplant in childhood: an analysis from the registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 33: 241-51.
5. R D Vanderlaan, C Manlhiot, L B Edwards, J Conway, B W McCrindle, et al. (2015) Risk factors for specific causes of death following pediatric heart transplant: An analysis of the registry of the International Society of Heart and Lung Transplantation. Pediatr Transplant 19: 896-905.
6. Kitamura S (2012) Heart transplantation in Japan: a critical appraisal for the results and future prospects. Gen Thorac Cardiovasc Surg 60: 639-644.
7. Wever-Pinzon O, Edwards LB, Taylor DO, Kfoury AG, Drakos SG, et al. (2017) Association of recipient age and causes of heart transplant mortality: Implications for personalization of post-transplant management-An analysis of the International Society for Heart and Lung Transplantation Registry. J Heart Lung Transplant 36: 407-417.
8. Saczkowski R, Dacey C, Bernier PL (2010) Does ABO-incompatible and ABO-compatible neonatal heart transplant have equivalent survival. Interact Cardiovasc Thorac Surg 10: 1026-1033.
9. Jeewa A, Manlhiot C, Kantor PF, Mital S, McCrindle BW, et al. (2014) Risk factors for mortality or delisting of patients from the pediatric heart transplant waiting list. J Thorac Cardiovasc Surg 147: 462-468.
10. Sivathasan C, Lim CP, Kerk KL, Sim DK, Mehra MR, et al. (2017) Mechanical circulatory support and heart transplantation in the Asia Pacific region. J Heart Lung Transplant 36: 13-18.